Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Singapore ETF (EWS) vs Heron Therapeutics Inc (HRTX) Price & Performance

iShares MSCI Singapore ETFTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Singapore ETF vs Heron Therapeutics Inc — how do they compare? iShares MSCI Singapore ETF trades at $33.68, while Heron Therapeutics Inc trades at $0.32 (market cap $61.47M). The key difference: iShares MSCI Singapore ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

EWSHRTX
Sector
Broad Market / FactorHealth
52-Week High
$33.92$1.49
52-Week Low
$26.71$0.32
Market Cap
$61.47M
Enterprise Value
$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Singapore ETF

EWS (iShares MSCI Singapore ETF) trades at $33.66, up 1.48% today and hitting a new 52-week high. Technical indicators show a bullish moving average consensus but overbought RSI signals. The ETF benefits from Singapore's economic resilience and AI-driven growth momentum, with institutional buying from firms like Amundi. Dividend yield remains attractive at 3.97% with consistent payout history.

Outlook remains positive given Singapore's market reforms and AI infrastructure growth, though concentrated financial sector exposure (54%) poses sector-specific risks. Near-term resistance at $34 may challenge further upside without fundamental catalysts. The ETF offers strategic Asian diversification but requires monitoring of regional economic developments.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.3409, up 3.24% today, but faces bearish technical signals with 18 sell indicators versus 6 buys. The company reported Q2 2026 revenue of $37.7 million but missed earnings expectations with a $0.03 per share loss. Despite strong analyst support (94.7% buy ratings), fundamental challenges persist with negative net income margins and elevated EV/EBITDA of 34.03.

Investment outlook remains cautious due to consistent earnings misses and negative cash flow from operations. The primary opportunity lies in analyst optimism and potential product growth, while risks include ongoing profitability challenges and competitive pressures in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Singapore ETF

EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.

Read more on EWS

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX